REGENERON PHARMACEUTICALS, INC. (REGN) Return on equity 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.4%FY2025 · since FY2016: 20.1% → 14.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.4% | -0.6 pp |
| FY2024 | 15.0% | -0.2 pp |
| FY2023 | 15.2% | -3.9 pp |
| FY2022 | 19.1% | -23.9 pp |
| FY2021 | 43.0% | +11.2 pp |
| FY2020 | 31.9% | +12.8 pp |
| FY2019 | 19.1% | -8.8 pp |
| FY2018 | 27.9% | +8.4 pp |
| FY2017 | 19.5% | -0.6 pp |
| FY2016 | 20.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice